¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Poisoning by agents primarily affecting the cardiovascular system"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • limbic system
    µÑ·¹°èÅë, º¯¿¬°è
  • lymphatic system
    ¸²ÇÁ°èÅë, ¸²ÇÁ°è
  • major histocompatibility system
    ÁÖÁ¶Á÷ÀûÇÕ°èÅë
  • monocyte-macrophage cell system
    ´ÜÇÙ±¸Å«Æ÷½Ä¼¼Æ÷°èÅë, ´ÜÇÙ±¸´ë½Ä¼¼Æ÷°èÅë
  • musculoskeletal system
    ±ÙÀ°»À´ë°èÅë, ±Ù°ñ°Ý°è
  • macrophage system
    Å«Æ÷½Ä¼¼Æ÷°èÅë, ´ë½Ä¼¼Æ÷°è
  • metric system
    ¹ÌÅ͹ý
  • nervous system
    ½Å°æ°èÅë, ½Å°æ°è
  • optical system
    ±¤Çаè
  • oxidation-reduction system
    »êȭȯ¿ø°è
  • picture archiving and communicating system
    ¿µ»óÀúÀå¹×Àü¼Ûü°è
  • portal system
    ¹®¸Æ°èÅë, ¹®¸Æ°è
  • projective system
    Åõ»çü°è
  • properdin system
    ÇÁ·ÎÆä¸£µò½Ã½ºÅÛ
  • parasympathetic nervous system
    ºÎ±³°¨½Å°æ°èÅë, ºÎ±³°¨½Å°æ°è
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • lymphatic system
    ¸²ÇÁ°èÅë
  • macrophage system
    Å«Æ÷½Ä¼¼Æ÷°èÅë
  • major histocompatibility system
    ÁÖÁ¶Á÷ÀûÇÕ°è
  • metric system
    ¹ÌÅ͹ý
  • monocyte-macrophage cell system
    ´ÜÇÙ±¸Å«Æ÷½Ä¼¼Æ÷°èÅë
  • musculoskeletal system
    ±ÙÀ°°ñ°Ý°èÅë
  • nervous system
    ½Å°æ°èÅë
  • nonrecirculating system
    ºñÀç¼øÈ¯½Äȸ·Î
  • nonspecific sensory system
    ºñƯÁ¤°¨°¢°è
  • oil immersion system
    À¯Ä§ÀåÄ¡
  • open system
    °³¹æÁ¦, °³¹æ½Ã½ºÅÛ, °³¹æÇüº´¿ø
  • optical system
    ±¤Çаè
  • oscillating system
    Áøµ¿°è
  • oxidation-reduction system
    »êȭȯ¿ø°è
  • parasympathetic nervous system
    ºÎ±³°¨½Å°æ°èÅë
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • anemia expert system
    ºóÇ÷Àü¹®°¡½Ã½ºÅÛ
  • annular phased array system, APAS
    À§»óµ¿±âÀ±»ó¹è¿­½Ã½ºÅÛ
  • archicortical system
    ¿ø½ÃÇÇÁú°è(¡­Í§)
  • array system
    ¹è¿­ ÀåÄ¡ (¹è¿­ ü°è)
  • gamma motoneuron system
    °¨¸¶¿îµ¿°è(¡­ê¡ÔÑͧ).
  • gas disposal system
    °¡½ºÃ³¸®ÀåÄ¡.
  • gastrointestinal system
    À§Àå°è.
  • gastrointestinal system
    À§Àå°è(êÖíóͧ).
  • gate control system
    °ü¹®Á¶Á¤ÀåÄ¡(μڦðàïÚíûöÇ).
  • general system theory
    ÀϹÝü°è(ÀÌ)·Ð(ìéÚõô÷ͧìµÖå)
  • genital system
    »ý½Ä°è(ßæãÖͧ).
  • genital system
    »ý½Ä°èÅë
  • genital system
    »ý½Ä±â°è(ßæãÖÐïͧ)
  • genitourinary system
    ºñ´¢»ý½Ä±â°èÅë(ù²èñßæãÖÐïͧ÷Ö).
  • genitourinary system
    ºñ´¢»ý½Ä±â°èÅë(ù²èñßæãÖÐïͧ÷Ö).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • meat poisoning
    °í±âÁßµ¶(ÊÙÌ¡ËÄ).
  • mercurial poisoning
    ¼öÀºÁßµ¶,È«µ¶.
  • mercurial poisoning
    ¼öÀºÁßµ¶, È«µ¶(â©Ô¸).
  • mercuric chloride poisoning
    ¿°È­ Á¦2¼öÀº(½ÂÈ«) Áßµ¶(ç¤ûù ð¯2â©ëÞ(ã°ûñ) ñéÔ¸)
  • mercury poisoning
    ¼öÀºÁßµ¶.
  • mercury poisoning
    ¼öÀºÁßµ¶(â©ëÞ ñéÔ¸)
  • metallic poisoning
    ±Ý¼ÓÁßµ¶(ÊÙÌ¡ËÄ).
  • metallic poisoning
    ±Ý¼ÓÁßµ¶(¡­ñéÔ¸).
  • mushroom poisoning
    ¹ö¼¸Áßµ¶(ÊÙÌ¡ËÄ).
  • mushroom poisoning
    ¹ö¼¸Áßµ¶(¡­ñéÔ¸)
  • mushroom poisoning ³ª
    ¹ö¼¸Áßµ¶(¡­ñéÔ¸).
  • opiate poisoning
    ¾ÆÆíÁßµ¶(ä¹ø¸ñéÔ¸).
  • organophosphate poisoning
    À¯±âÀλ꿰Áßµ¶
  • oxygen intoxication =o. poisoning
    »ê¼ÒÁßµ¶(¡­ñéÔ¸).
  • oxygen poisoning
    »ê¼ÒÁßµ¶(Áõ)(¡­ñéÔ¸ñø).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
CIRSE Cardiovascular and Interventional Radiological Society of Europe
CONVINCE Controlled Onset Verapamil Investigation of Cardiovascular Endpoints
CRC cardiovascular reflex conditioning; clinical research center; colorectal carcinoma; concentrated red...
CV cardiac volume; cardiovascular; carotenoid vesicle; cell volume; central venous; cephalic vein; cere...
CVA cardiovascular accident; cerebrovascular accident; chronic villous arthritis; common variable agamma...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
AHCCCS Arizona Health Care Cost Containment System
ANS Autonomic Nervous System
BEVS Baculovirus Expression Vector System
BIS Behavioral Inhibition System
BRFSS Behavioral Risk Factor Surveillance System
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • hypothalamohypophyseal system
    ½Ã»ó ÇϺΠ³úÇϼöü°è
  • hypothalamopituitary system
    ½Ã»ó ÇϺΠ³úÇϼöü°è
  • hypothalamus pituaitary system
    ½Ã»ó ÇϺΠ³úÇϼöü°è
  • immune system
    ¸é¿ª °èÅë, ¸é¿ª°è
    °¨¿°À̳ª Áúº´À¸·ÎºÎÅÍ ½Åü¸¦ ¹æ¾îÇϴµ¥ °ü¿©ÇÏ´Â ¿©·¯ ¼¼Æ÷¿Í Àå±â Áý´Ü.
  • immunologic system
    ¸é¿ª°è
    ¼¼Æ÷ ¼ººÐ ¹× ºÐÀÚ ¼ººÐÀÇ º¹ÇÕ Ã¼°è·Î¼­ ÀÌÀÇ ÀÏÂ÷ ±â´ÉÀº Àڱ⸦ ºñÀÚ±â·ÎºÎÅÍ ±¸º°ÇÏ°í ¿ÜºÎ »ý¹° ¶Ç´Â ¹°Áú¿¡ ´ëÇØ ¹æ¾îÇÏ´Â °ÍÀÌ´Ù.
  • implant system
    ÀÓÇöõÆ® ½Ã½ºÅÛ
  • improved classificaion system
    °³¼±µÈ ºÐ·ù ü°è
  • kinesodic system
    ô¼ö ¿îµ¿°è
  • kinetic system
    ¿îµ¿°è
    ³ú, °©»ó¼±, ºÎ½Å, °£, ÃéÀå µîÀÇ ±â°ü°èÅëÀ¸·Î, ÀáÀç·ÂÀ» ¿îµ¿°ú ¿­·Î º¯È­½ÃŰ´Â ±â´ÉÀ» ³ªÅ¸³½´Ù. ´Éµ¿Àû ¿îµ¿À» ÀÏÀ¸Å³ ¼ö ÀÖ´Â ½Å°æ±Ù°è.
  • lacrimal system
    ´«¹° ±â°ü
  • length monitoring system
    ±æÀÌ °¨Áö°è
  • lymphatic system
    ¸²ÇÁ°è
    °¨¿°À̳ª Áúº´°ú ½Î¿ì´Â ¼¼Æ÷¸¦ ¸¸µé°Å³ª ÀúÀåÇÏ´Â Á¶Á÷°ú Àå±â. °ñ¼ö, ºñÀå, Èä¼±, ±×¸®°í ¸²ÇÁÀý µîÀÌ ¸²ÇÁ°èÀÇ ´ëÇ¥Àû Àå±âÀÌ´Ù. ¸²ÇÁ°è¿¡´Â ÀÌ·¯ÇÑ ¿©·¯ Á¶Á÷°ú Àå±â¸¦ ¿¬°áÇÏ´Â Åë·Î Áï ¸²ÇÁ°üÀÌ ÀÖÀ¸¸ç À̸¦ ÅëÇØ ¸²ÇÁ°¡ ¿î¹ÝµÈ´Ù.
  • lymphoreticular system
    ¸²ÇÁ ¼¼¸Á ³»Çǰè
  • masticatory musculoskeletal system
    ÀúÀÛ±Ù °ñ°Ý°è
  • masticatory system
    ÀúÀÛ°è
    Ä¡¾Æ, Ä¡ÁÖ Á¶Á÷, ¾Ç°ñ, ÃøµÎÇϾǰüÀý, ÀúÀÛ±Ù ÀÔ¼ú, Çô ¹× À̵é Á¶Á÷°ú °ü·ÃµÈ Ç÷°ü, ½Å°æµé·Î ÀÌ·ç¾îÁø ±â´ÉÀû ´ÜÀ§.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
anti-infective agents, urinary Substances capable of killing agents causing urinary tract infections or of preventing them from spreading.
(12 Dec 1998)
antilipaemic agents Substances that counteract high levels of lipids in the blood.
(12 Dec 1998)
antimanic agents Agents that are used to treat bipolar disorders or mania associated with other affective disorders.
(12 Dec 1998)
antimutagenic agents Agents that reduce the frequency or rate of spontaneous or induced mutations independently of the mechanism involved.
(12 Dec 1998)
antineoplastic and immunosuppressive agents Collective grouping for substances used to arrest the proliferation of malignant cells and those that suppress the immune response.
(12 Dec 1998)
anti-obesity agents Agents that increase energy expenditure and weight loss by neural and chemical regulation. Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (niddm) to treat obesity.
(12 Dec 1998)
antiparasitic agents Drugs used to treat or prevent parasitic infections.
(12 Dec 1998)
antiparkinson agents Agents used in the treatment of parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.
(12 Dec 1998)
anti-platelet agents Medications that, like aspirin, reduce the tendency of platelets in the blood to clump and clot.
(12 Dec 1998)
antiplatyhelmintic agents Agents used to treat cestode, trematode, or other flatworm infestations in man or animals.
(12 Dec 1998)
antiprotozoal agents Agents destructive to protozoans or that check their growth or reproduction, especially those causing protozoan infections in man and animal.
(12 Dec 1998)
antipsychotic agents Agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in schizophrenia, senile dementia, transient psychosis following surgery or myocardial infarction, etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.
(12 Dec 1998)
antipsychotic agents, butyrophenone Those butyrophenone derivatives used in the treatment of psychoses.
(12 Dec 1998)
antipsychotic agents, phenothiazine Phenothiazine derivatives used in the treatment of psychoses.
(12 Dec 1998)
antirheumatic agents Drugs that are used to treat rheumatoid arthritis.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • profit system
    =FREE ENTERPRIZE
  • proportional reserve system
    (Á¤È­ Áغñ¿Í ÁöÆó ¹ßÇà°íÀÇ) ºñ·Ê ÁغñÁ¦
  • protective system
    º¸È£ ¹«¿ª Á¦µµ
  • public address system
    (°­´çµîÀÇ)È®¼º ÀåÄ¡
  • publicaddress system
    È®¼º ÀåÄ¡
  • radar data processing system
    Ç×°ø·Î ·¹ÀÌ´õ Á¤º¸ ó¸® ½Ã½ºÅÛ
  • rationing system
    ¹è±Þ Á¦µµ
  • real-time system
    ½Ç½Ã°£(Áï½Ãó¸®)½Ã½ºÅÛ(´Ü¸»¿¡¼­ º¸³»¿Â µ¥ÀÌÅ͸¦ Áï½Ã ÄÄÇ»ÅÍ¿¡ ó¸®ÇÏ¿© ´Ü¸»·Î µÇµ¹¸®´Â ½Ã½ºÅÛ)
  • remote manipulator system
    ¿ø°Ý Á¶ÀÛ ½Ã½ºÅÛ
  • respiratory system
    È£Èí±â°è
  • reticuloendothelial system
    (¼¼)¸Á ³»(ÇÇ)°è
  • retrieval system
    Á¤º¸ °Ë»ö ½Ã½ºÅÛ
  • solar system
    žç°è
  • spoils system
    ¿±°ü Á¦µµ(¿©´çÀÌ Â÷ÁöÇÏ´Â)
  • sprinkler system
    ÀÚµ¿ »ì¼ö ¼ÒÈ­ ÀåÄ¡
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á